-

ONCOMATRYX Raises €25 Million to Foster OMTX705 Clinical Trials

ZAMUDIO, Spain--(BUSINESS WIRE)--ONCOMATRYX, a biopharmaceutical company developing novel ADCs against the tumor microenvironment, has successfully raised €25 million, to fund Phase Ib-II clinical trials of OMTX705, a first-in-class ADC targeting FAP.

The funding round was led by the company’s existing investors and included a €10 million strategic investment from Centro para el Desarrollo Tecnológico y la Innovación. This endorsement highlights the confidence in ONCOMATRYX pioneering ADCs to treat metastatic solid tumors.

“We are thrilled to count on the continued support of our existing investors and welcome CDTI through Innvierte, an investment program of CDTI” said Dr. Laureano Simon, CEO of ONCOMATRYX. “This funding validates our clinical progress and equips us to execute on critical milestones and deliver transformative therapies to patients.”

About Oncomatryx

Oncomatryx has developed a proprietary Antibody-Drug Conjugates platform that targets Cancer-Associated Fibroblasts in the microenvironment of metastatic solid tumors.

Oncomatryx pioneering ADCs against immunosuppressive CAFs are developed in collaboration with prestigious universities, hospitals and research centers in USA and Europe.

Phase I clinical results of OMTX705, a novel ADC targeting Fibroblast Activation Protein in the Cancer-Associated Fibroblasts, will be presented at major Oncology conferences along 2025.

https://clinicaltrials.gov/ct2/show/NCT05547321?term=oncomatryx&draw=2&rank=1

For more information and updates about Oncomatryx and its clinical programs, please contact:

Contacts

Pedro Esnaola
CPAO
pesnaola@oncomatryx.com

Industry:

ONCOMATRYX BIOPHARMA, S.L.

Details
Headquarters: Derio, Spain
CEO: Laureano Simon
Employees: 50
Organization: PRI
Release Versions
English

Contacts

Pedro Esnaola
CPAO
pesnaola@oncomatryx.com

More News From ONCOMATRYX BIOPHARMA, S.L.

Antibody Designed by Spanish Biopharma Oncomatryx Shows That Attacking the Tumor Environment Also Kills Cancer Cells

ZAMUDIO, Spain--(BUSINESS WIRE)--Oncomatryx, the Basque biopharmaceutical company pioneering the treatment of solid tumors through their microenvironment, has taken part, together with German research institutions, in a study showing in patient tumor tissue that destroying the cells that protect the tumor also kills cancer cells. This was achieved by OMTX305, a bispecific antibody designed by the company that directs the patient’s own T cells against the fibroblasts surrounding the tumor. The w...

ONCOMATRYX Raises $67 Million to Foster the Clinical Development of Its Quantum ADCs in Spain

DERIO, Spain--(BUSINESS WIRE)--ONCOMATRYX, a Spanish biopharmaceutical company developing Quantum ADCs against the tumor microenvironment, has successfully raised $67 million to foster the clinical development of novel candidates. The funding round was led by the company’s institutional investors, including a $28 million strategic investment from the Spanish Government through Centro para el Desarrollo Tecnologico e Innovacion (CDTI), $18 million from Kutxa Fundazioa, $12 million from the Basqu...

Oncomatryx Biopharma Awarded €12.5 Million EIC Accelerator Funding to Advance Groundbreaking ADCs

BILBAO, Spain--(BUSINESS WIRE)--Oncomatryx Biopharma, a biotechnology company pioneering next-generation Antibody-Drug Conjugates (ADCs) for oncology, has been awarded funding from the European Innovation Council (EIC) Accelerator under the EU’s Horizon Europe 2021-2027 Research and Innovation Program. As part of this highly competitive program, Oncomatryx will receive €2.5 million in grant funding, along with a €10 million equity investment in its upcoming financing round. The EIC Accelerator...
Back to Newsroom